Takeda's Hyqvia Phase 3 Trial In CIDP Patients Meets Primary Endpoint

Takeda Pharmaceutical Co. Ltd. (TAK) Thursday said its double-blind phase 3 trial of Hyqvia met the primary endpoint for the maintenance treatment of chronic inflammatory demyelinating polyradiculoneuropathy or CIDP.

The trial used 10 percent human Immune Globulin Infusion with Recombinant Human Hyaluronidase.

The results showed that Hyqvia reduced relapse of neuromuscular disability and impairment. The pharma company said analyses from ADVANCE-1 are ongoing.

The trial was in 132 adult patients CIDP autoimmune disease who had been on a stable
dosing regimen of intravenous immunoglobulin therapy for at least three
months prior to infusion.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
American Honda Motor Co, Inc. has recalled about 2,900 units of 2022 model year Honda TRX90X All-Terrain Vehicles (ATVs) sold in the United States for possible crash and injury hazard, according to a statement issued by the U.S. Consumer Product Safety Commission or CPSC. The Laundress, a unit of Conopco Inc. d/b/a Unilever, is recalling around 8 million laundry and household cleaning products citing risk of exposure to bacteria, U.S. Consumer Product Safety Commission. The recall involves Laundress laundry detergent, fabric conditioner and other cleaning products. Tesla Inc. has delivered its first Semi, a heavy-duty electric truck, to its customer PepsiCo Inc. during an event at its Nevada Gigafactory. The delivery of 500-mile fully electric Semi truck comes five years after the launch of the truck's prototype in 2017. During Thursday night's Semi Delivery Event at Tesla's Sparks, Nevada factory, CEO Elon Musk, with Dan Priestly, ...
Follow RTT